Climb Bio Target of Unusually High Options Trading (NASDAQ:CLYM)

Key Points

• Put-option activity surged to 7,091 contracts, 1,046% above average volume, signaling heightened hedging or bearish speculation around Climb Bio.
• Analysts remain broadly bullish, with an average “Buy” rating and $23.08 price target; recent targets range from $20 to $25.
• CLYM shares fell 4.4% to $15.38, despite institutional investors owning 69.76% of the stock and the company beating quarterly EPS expectations.

Climb Bio, Inc. (NASDAQ:CLYM - Get Free Report) was the recipient of unusually large options trading activity on Thursday. Stock investors bought 7,091 put options on the stock. This represents an increase of 1,046% compared to the average volume of 619 put options.

Analysts Set New Price Targets

Several research firms have recently weighed in on CLYM. Truist Financial raised their price objective on shares of Climb Bio from $17.00 to $25.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Wall Street Zen raised shares of Climb Bio from a "sell" rating to a "hold" rating in a research note on Saturday, May 9th. Chardan Capital began coverage on shares of Climb Bio in a report on Tuesday, May 5th. They set a "buy" rating and a $22.00 target price for the company. Wedbush restated an "outperform" rating and issued a $20.00 price target on shares of Climb Bio in a research report on Wednesday, August 19th. Finally, HC Wainwright upped their price target on Climb Bio from $20.00 to $24.00 and gave the company a "buy" rating in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $23.08.

Climb Bio Trading Down 4.4%

CLYM stock traded down $0.70 during mid-day trading on Thursday, reaching $15.38. 643,333 shares of the stock traded hands, compared to its average volume of 943,351. Climb Bio has a 52-week low of $1.54 and a 52-week high of $18.33. The stock's fifty day moving average is $13.69 and its 200-day moving average is $10.37. The company has a market cap of $883.25 million, a P/E ratio of -18.53 and a beta of 0.08.

Climb Bio (NASDAQ:CLYM - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03. Equities research analysts expect that Climb Bio will post -0.82 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CLYM. Braidwell LP grew its stake in Climb Bio by 102.6% during the 2nd quarter. Braidwell LP now owns 3,099,027 shares of the company's stock valued at $40,411,000 after acquiring an additional 1,569,352 shares in the last quarter. MPM Bioimpact LLC purchased a new stake in shares of Climb Bio in the fourth quarter worth approximately $10,686,000. BlackRock Inc. acquired a new stake in shares of Climb Bio during the second quarter worth approximately $30,708,000. Price T Rowe Associates Inc. MD grew its position in Climb Bio by 265.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,923,639 shares of the company's stock valued at $7,695,000 after purchasing an additional 1,396,722 shares in the last quarter. Finally, ADAR1 Capital Management LLC increased its stake in Climb Bio by 972.8% in the 4th quarter. ADAR1 Capital Management LLC now owns 1,432,475 shares of the company's stock valued at $5,730,000 after buying an additional 1,298,945 shares during the period. Hedge funds and other institutional investors own 69.76% of the company's stock.

Trending Headlines about Climb Bio

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Climb Bio’s Phase 2 trial in China is advancing, providing continued progress for the company’s clinical pipeline. However, investors are also assessing whether that progress is already reflected in the valuation. Climb Bio (CLYM) Advances Phase 2 Trial In China, Is The Valuation Already Priced In?
• Positive Sentiment: HC Wainwright raised its Climb Bio loss estimates across several periods, implying better-than-previously-expected results: FY2026 EPS to $(0.76) from $(0.93), Q3 2026 to $(0.20) from $(0.23), Q4 2026 to $(0.19) from $(0.22), and FY2027 to $(0.98) from $(0.99). The firm reiterated its Buy rating and $24 price target, well above the recent trading level.
• Neutral Sentiment: Short interest was reported at zero shares as of August 25, unchanged from August 10. This indicates no measurable short-selling pressure, although the data provides little additional directional information.
• Neutral Sentiment: Unusually heavy call-option activity occurred Wednesday, with 3,024 calls traded versus typical volume of 360. The activity may reflect bullish speculation, but options volume alone does not confirm that traders expect a sustained advance.
• Negative Sentiment: Put-option activity surged Thursday to 7,091 contracts, approximately 1,046% above the average daily volume of 619. The sharp increase points to heightened hedging or bearish speculation and is the clearest near-term negative market signal.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company's mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio's approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source